Compare Remitly Global Inc (RELY) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Remitly Global Inc vs Repligen Corporation Common Stock — how do they compare? Remitly Global Inc trades at $23.48 (market cap $4.97B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is far larger — about 2.3× Remitly Global Inc's market cap, and Remitly Global Inc is more actively traded (2,090,383 versus 1,216,919). Which is the better fit depends on your goals — on Pluang, investors hold Remitly Global Inc for 53 Days and Repligen Corporation Common Stock for 0 Days on average.
| RELY | RGEN | |
|---|---|---|
Market Cap | $4.97B | $11.31B |
Volume | 2,090,383 | 1,216,919 |
Sector | Technology | Health |
52-Week High | $26.92 | $194.57 |
52-Week Low | $12.20 | $102.87 |
Typical Hold Time | 53 Days | 0 Days |
Enterprise Value | $4.34B | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RELY trades at $23.76, up 0.93% with strong technical momentum and bullish moving averages. The company demonstrates accelerating revenue growth, reaching $1.64B in 2025 with net income turning positive at $68M. Recent earnings beats and a 92% analyst buy rating support the bullish case, while the stock approaches key resistance at $24-25 levels.
Outlook remains positive with 20% revenue growth and expanding profit margins driving valuation. Key risks include competitive pressures in digital payments and potential market volatility. The consensus price target of $30.50 suggests 28% upside potential from current levels, supported by strong institutional interest and positive business momentum.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
